USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $-0.45 | - | $-0.34 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $1.68M | - | $1.82M |
Aclaris Therapeutics, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 6 | $-0.45 | $-0.47 | $-0.40 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 6 | $-1.84 | $-1.94 | $-1.55 |
| Dec 2023 | 6 | $-1.78 | $-1.95 | $-1.34 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 0 / 0 | $-0.45 | $-0.36 | $-0.36 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-1.84 | $-1.67 | $-1.67 |
| Dec 2023 | 0 / 0 | $-1.78 | $-1.60 | $-1.53 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 6 | $1.68M | $1.40M | $1.90M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 6 | $6.76M | $5.60M | $7.80M |
| Dec 2023 | 6 | $6.95M | $5.60M | $8.20M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 5, 2022 | Mar 2022 | $-0.40 | - | - |
| Feb 24, 2022 | Dec 2021 | $-0.36 | $-0.37 | -2.78% |
| Nov 2, 2021 | Sep 2021 | $-0.28 | $-0.35 | -24.25% |
| Aug 5, 2021 | Jun 2021 | $-0.28 | $-0.34 | -21.43% |
| May 7, 2021 | Mar 2021 | $-0.28 | $-0.57 | -103.57% |
| Feb 25, 2021 | Dec 2020 | $-0.26 | $-0.30 | -15.38% |
| Nov 4, 2020 | Sep 2020 | $-0.31 | $-0.25 | 18.03% |
| Aug 7, 2020 | Jun 2020 | $-0.36 | $-0.28 | 21.13% |
| May 7, 2020 | Mar 2020 | $-0.38 | $-0.37 | 1.33% |
| Feb 25, 2020 | Dec 2019 | $-0.39 | $-0.45 | -16.37% |
| Nov 7, 2019 | Sep 2019 | $-0.69 | $-1.34 | -94.20% |
| Aug 8, 2019 | Jun 2019 | $-0.75 | $-1.21 | -62.20% |
| May 8, 2019 | Mar 2019 | $-0.80 | $-0.91 | -13.40% |
| Mar 18, 2019 | Dec 2018 | $-0.98 | $-0.99 | -0.68% |
| Nov 6, 2018 | Sep 2018 | $-1.33 | $-1.06 | 20.10% |
| Aug 3, 2018 | Jun 2018 | $-1.09 | $-1.01 | 7.62% |
| May 8, 2018 | Mar 2018 | $-1.00 | $-0.98 | 2.32% |
| Mar 12, 2018 | Dec 2017 | $-0.88 | $-0.74 | 15.91% |
| Nov 7, 2017 | Sep 2017 | $-0.87 | $-0.63 | 27.59% |
| Aug 8, 2017 | Jun 2017 | $-0.73 | $-0.56 | 23.29% |
| May 9, 2017 | Mar 2017 | $-0.59 | $-0.48 | 18.64% |
| Mar 15, 2017 | Dec 2016 | $-0.64 | $-0.49 | 22.83% |
| Nov 3, 2016 | Sep 2016 | $-0.67 | $-0.50 | 25.65% |
| Aug 11, 2016 | Jun 2016 | $-0.65 | $-0.62 | 4.13% |
| May 11, 2016 | Mar 2016 | $-0.50 | $-0.65 | -30.00% |
| Mar 23, 2016 | Dec 2015 | $-0.45 | $-0.28 | 37.78% |
| Oct 13, 2015 | Sep 2015 | $-2.84 | $-5.11 | -79.93% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 24, 2022 | Dec 2021 | $-1.61 | $-1.63 | - |
| Feb 25, 2021 | Dec 2020 | $-1.16 | $-1.20 | - |
| Feb 25, 2020 | Dec 2019 | $-4.70 | $-3.91 | - |
| Mar 18, 2019 | Dec 2018 | $-4.02 | $-4.04 | - |
| Mar 12, 2018 | Dec 2017 | $-2.57 | $-2.41 | - |
| Mar 15, 2017 | Dec 2016 | - | $-2.26 | - |
| Mar 23, 2016 | Dec 2015 | - | $-5.39 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 5, 2022 | Mar 2022 | $1.66M | - | - |
| Feb 24, 2022 | Dec 2021 | $1.79M | $1.50M | 0.84% |
| Nov 2, 2021 | Sep 2021 | $1.77M | $1.66M | 0.94% |
| Aug 5, 2021 | Jun 2021 | $1.75M | $1.82M | 1.04% |
| May 7, 2021 | Mar 2021 | $1.48M | $1.78M | 1.20% |
| Feb 25, 2021 | Dec 2020 | $1.39M | $1.58M | 1.14% |
| Nov 4, 2020 | Sep 2020 | $1.47M | $1.45M | 0.99% |
| Aug 7, 2020 | Jun 2020 | $1.23M | $2.05M | 1.66% |
| May 7, 2020 | Mar 2020 | $1.13M | $1.41M | 1.25% |
| Feb 25, 2020 | Dec 2019 | $3.47M | $1.09M | 0.32% |
| Nov 7, 2019 | Sep 2019 | $5.82M | $983.00K | 0.17% |
| Aug 8, 2019 | Jun 2019 | $5.55M | $5.87M | 1.06% |
| May 8, 2019 | Mar 2019 | $5.12M | $5.04M | 0.98% |
| Mar 18, 2019 | Dec 2018 | $3.46M | $3.67M | 1.06% |
| Nov 6, 2018 | Sep 2018 | $1.75M | $1.63M | 0.93% |
| Aug 3, 2018 | Jun 2018 | $3.68M | $3.68M | 1.00% |
| May 8, 2018 | Mar 2018 | $1.00M | $1.12M | 1.12% |
| Mar 12, 2018 | Dec 2017 | $520.00K | $999.00K | 1.92% |
| Nov 7, 2017 | Sep 2017 | $880.00K | $684.00K | 0.78% |
| Aug 8, 2017 | Jun 2017 | $0.00 | $0.00 | - |
| May 9, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 15, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 3, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 11, 2016 | Jun 2016 | - | $0.00 | - |
| May 11, 2016 | Mar 2016 | - | $0.00 | - |
| Mar 23, 2016 | Dec 2015 | - | $0.00 | - |
| Oct 13, 2015 | Sep 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 24, 2022 | Dec 2021 | $7.05M | $6.76M | -4.10% |
| Feb 25, 2021 | Dec 2020 | $6.29M | $6.48M | 3.05% |
| Feb 25, 2020 | Dec 2019 | $17.58M | $4.23M | -75.96% |
| Mar 18, 2019 | Dec 2018 | $9.87M | $10.09M | 2.24% |
| Mar 12, 2018 | Dec 2017 | $1.01M | $1.68M | 66.63% |
| Mar 15, 2017 | Dec 2016 | - | $0.00 | - |
| Mar 23, 2016 | Dec 2015 | - | $0.00 | - |
ACRS's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Aclaris Therapeutics, Inc's next quarterly earnings is $-0.45, with a low EPS estimation of $-0.47, and a high estimation of $-0.40.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.45, the last 2 month trend is $-0.36, and the 3 month trend is $-0.36.
Based on analysts, the average revenue estimation is $1.68M, with a low revenue estimation of $1.40M, and a high estimation of $1.90M.
Aclaris Therapeutics, Inc's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.
Aclaris Therapeutics, Inc's previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.
ACRS's earnings per share (EPS) was $-1.63, missing the consensus analysts forecast of $-1.61 by 1.24% , and lower than the previous year's EPS (Dec 2020) by 35.83%.
Revenues were $6.76M, worse than the forecast of $7.05M by -4.10%, and up by 4.30% from previous year's revenue.
The company reported a net income of $-90.86M.
Aclaris Therapeutics, Inc reported a free cash flow of $-52.44M for its fiscal year, compared to $-39.09M a year ago.
The company ended the fiscal year with $693.00K in total debt, a decrease of -93.84% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
